Home > List of Excluded Articles - Comparative...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Qayyum R, Wilson LM, Bolen S, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Sep. (Comparative Effectiveness Reviews, No. 14.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Appendix CList of Excluded Articles

References

1.
Anonymous. 1–2–3: study results and clinical application: the “Start & Stay” approach. Journal of Diabetes Nursing 2006;(1):3p. No original data .
2.
Anonymous. The 1–2–3 study: achieving glycaemic goals in type 2 diabetes. Journal of Diabetes Nursing 2006;(1):1p. No original data .
3.
Anonymous. Key abstract: the EUROMIX study. Journal of Diabetes Nursing 2005;[3]. No original data .
4.
Anonymous. Rapid acting insulin analogue effective in a range of body types launched. Pharm. J. 2005;275(7369):401. No original data .
5.
Anonymous. DTB questions first-line use of insulin analogues. Pharm. J. 2004;273(7321):552. No original data .
6.
Anonymous. Lispro, a rapid-onset insulin. Med. Lett. Drugs Ther. 1996;38(986):97–98. No original data . [PubMed: 8906134]
7.
Anonymous. The why and how of early intervention with insulin analogs. Diabetes Educator 2007;3352S–75s. No original data .
8.
Anonymous. CDC Fact Book 2000/2001. Department of Health and Human Services Centers for Disease Control and Prevention, 2000 Sep (138 p) No original data .
9.
Anonymous. Diabetes Overview. US Department of Health and Human Services National Institute of Diabetes and Digestive and Kidney Diseases, 2000 Sep (8 p) No original data .
10.
Anonymous. Is biphasic, prandial, or basal insulin best for poorly controlled type 2 diabetes? J Fam Pract 2008;57(2):84. No original data . [PubMed: 18254190]
11.
Abraham MR, Al-Sharafi BA, Saavedra GA. et al. Lispro in the treatment of insulin allergy. Diabetes Care. 1999;22(11):1916–1917. No original data . [PubMed: 10546039]
12.
Akram J. Prevention of hypoglycaemia in insulin-treated patients during Ramadan: results from a multicentre study: 2. Practical Diabetes International. 1998;15(1):S19. Did not evaluate a premixed insulin analogue .
13.
Aristides M, Weston AR, FitzGerald P. et al. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004;7(4):442–54. Does not apply to a key question . [PubMed: 15449636]
14.
Bain SC, Kamal AD. Safety and side effects of the insulin analogues. Expert Opin Drug Saf. 2006;5(3):349–350. No original data . [PubMed: 16610964]
15.
Bell D, Bode B, Clements RS. et al. Premixed vs. self-mixed insulin in the treatment of type II diabetes mellitus: A randomized trial. Today's Ther Trends. 1991;9(1):63–73. Did not evaluate a premixed insulin analogue .
16.
Bolli GB, Di Marchi RD, Park GD. et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42(10):1151–1167. No original data . [PubMed: 10525654]
17.
Bullano MF, Fisher MD, Grochulski WD. et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm. 2006;63(24):2473–82. Did not evaluate a premixed insulin analogue . [PubMed: 17158695]
18.
Calle-Pascual AL, Bagazgoitia J, Calle JR. et al. Use of insulin lispro in pregnancy. Diabetes Nutr Metab. 2000;13(3):173–7. No original data . [PubMed: 10963394]
19.
Cappelleri JC, Cefalu WT, Rosenstock J. et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clinical therapeutics. 2002;24(4):552–64. Did not evaluate a premixed insulin analogue . [PubMed: 12017400]
20.
Chan WB, Chow CC, Yeung VTF. et al. Effect of insulin lispro on glycaemic control in Chinese diabetic patients receiving twice-daily regimens of insulin. Chin Med J. 2004;117(9):1404–1407. Did not evaluate people with type 2 diabetes . [PubMed: 15377436]
21.
Clements MR, Tits J, Kinsley BT. et al. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab. 2008;10(3):229–37. Did not evaluate people with type 2 diabetes . [PubMed: 18269638]
22.
Cobden D, Lee WC, Balu S. et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948–62. Did not compare a premixed insulin analogue to another antidiabetic agent . [PubMed: 17594200]
23.
Coscelli C, Calabrese G, Fedele D. et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care. 1992;15(11):1628–30. Did not evaluate a premixed insulin analogue . [PubMed: 1468295]
24.
Culy CR, Jarvis B. Management of diabetes mellitus: Defining the role of insulin lispro mix75/25 (Humalog(registered trademark) Mix75/25(trademark)) Dis Manage Health Outcomes. 2001;9(12):711–730. No original data .
25.
Currie CJ, McEwan P, Poole C. et al. Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin. 2006;22(5):967–9. author reply 968–9. No original data . [PubMed: 16709318]
26.
Davidson MB. Twice-Daily NPH or mixture insulins versus triple therapy: apples versus oranges: response to Poulsen et al. Diabetes Care. 2004;27(7):1846. author reply 1847–8. No original data . [PubMed: 15220288]
27.
DeWitt DE. Case study: Treating new-onset catabolic type 2 diabetes with glargine and lispro. Clin Diabetes. 2006;24(4):180–181. No original data .
28.
Dunbar JM, Madden PM, Gleeson DT. et al. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes care. 1994;17(8):874–8. Did not evaluate people with type 2 diabetes . [PubMed: 7956634]
29.
Ebeling P, Tuominen JA, Koivisto VA. Insulin analogues and carcinoma of the breast. Diabetologia. 1996;39(1):124–125. No original data . [PubMed: 8720615]
30.
Edelman S. Does a patient-administered titration algorithm of insulin glargine improve glycemic control? Nat Clin Pract Endocrinol Metab. 2006;2(2):78–9. Did not evaluate a premixed insulin analogue . [PubMed: 16932261]
31.
Ejskjaer N, Rasmussen M, Kamp N. et al. Comparison of thrice daily ‘high’ vs. ‘medium’ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(6):438–45. Did not compare a premixed insulin analogue to another antidiabetic agent . [PubMed: 14617230]
32.
Gale E, Del Prato S. Emerging clinical uses for insulin lispro. Pract Diabetes Int. 1997;14(4 SUPPL):S4–S10. No original data .
33.
Garber AJ. Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes. Clin Ther. 2005;27(Suppl 2):S39–41. No original data . [PubMed: 16519036]
34.
Garg SK. New insulin analogues. Diabetes Technol Ther. 2005;7(5):813–7. No original data. [PubMed: 16241890]
35.
Groop L, Harno K, Tolppanen EM. The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta Endocrinol. 1984;106(1):97–101. Did not evaluate a premixed insulin analogue . [PubMed: 6428120]
36.
Hamid Z, Simmons DL. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients: response to Rosenstock et al. Diabetes Care. 2006;29(10):2331. author reply 2332. No original data . [PubMed: 17003324]
37.
Herz M. Clinical update on Humalog Mix25 a novel pre-mixed formulation of insulin lispro and NPL. Int J Clin Pract Suppl 1999;1048–13; discussion 18–20. No original data . [PubMed: 12669732]
38.
Home PD, Bailey CJ, Donaldson J. et al. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. 2007;24(6):618–25. Did not evaluate a premixed insulin analogue . [PMC free article: PMC1974817] [PubMed: 17403121]
39.
Home P D. Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267. Diabetologia 2007;50(7):1561–2. No original data . [PubMed: 17384924]
40.
Ishii H, Yamamura A, Malone JK. Quality-of-life (QOL) assessment of type 1 and type 2 diabetes mellitus patients in regard to insulin lispro mixture-25 and mixture-50 twice daily therapy. J Jpn Diabetes Soc. 2005;48(8):607–616. Non-English article .
41.
Iwamoto Y, Kawamori R, Kadowaki T. et al. Clinical study on insulin lispro Mixture-25 and Mixture-50 administered twice daily in insulin requiring patients with type 1 and 2 diabetes mellitus. Rinsho-Iyaku. 2002;18(3):395–409. Non-English article .
42.
Janka H U, Hogy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 2007. Did not evaluate a premixed insulin analogue . [PubMed: 17530309]
43.
JiXiong X, Jianying L, Yulan C. et al. The human insulin analog aspart can induce insulin allergy. Diabetes Care. 2004;27(8):2084–5. Does not apply to a key question . [PubMed: 15277447]
44.
Jungmann E, Bolle J, Schmitz C. et al. Intensified insulin therapy (IIT) in type II Diabetes mellitus: pre- or postprandial injection of aspart insulin? Medizinische Klinik. 2004;99:109. Non-English article .
45.
Katahira M, Hara I, Nishizaki T. Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R) Diabetic Med. 2005;22(10):1455–1457. No original data . [PubMed: 16176214]
46.
Kazda CM, Forst T, Gierhake C. et al. Improving blood glucose and reducing incidence of hypoglycemia in type 2 diabetics using insulin lispro 25%/NPL 75%: VERBESSERUNG DER BLUTGLUKOSEEINSTELLUNG UND SENKUNG DER HYPOGLYKAMIERATE BEI TYP-2-DIABETIKERN UNTER INSULIN LISPRO 25. Diabetes Stoffwechsel. 2003;12(5):233–238. Non-English article .
47.
Kitowicz A, Criswell DF. Question: is insulin glargine more effective? J Okla State Med Assoc. 2007;100(1):26–7. No original data . [PubMed: 17378499]
48.
Kitzmiller JL, Buchbinder A, Khoury J. et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy (multiple letter) [4] Am J Obstet Gynecol. 2001;185(3):774–775. No original data . [PubMed: 11568815]
49.
Kitzmiller JL, Main E, Ward B. et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care. 1999;22(5):874–6. Did not evaluate a premixed insulin analogue . [PubMed: 10332713]
50.
Koivisto VA. International experience with insulin lispro. Pract Diabetes Int. 1998;15(1 SUPPL):S15–S17. No original data .
51.
Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care. 1999;22(3):459–62. Does not apply to a key question . [PubMed: 10097929]
52.
Kokic S, Bukovic D, Radman M. et al. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Coll Antropol. 2003;27(1):181–7. Did not evaluate a premixed insulin analogue . [PubMed: 12974145]
53.
Lee WC, Balu S, Cobden D. et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712–25. Did not compare a premixed insulin analogue to another antidiabetic agent . [PubMed: 17157128]
54.
Levinson PD. Premixed or self-mixed insulin for elderly patients. Ann Intern Med. 1993;118(SUPPL 3):80. No original data .
55.
Lindholm A, Jensen LB, Home PD. et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25(5):876–82. Does not apply to a key question . [PubMed: 11978684]
56.
Luddeke H J. Improving post-prandial control with Humalog and Humalog mixtures. Int J Clin Pract Suppl 2000;(112):23–8. No original data . [PubMed: 11064948]
57.
McCormack J, Bassett K. The evidence for insulin lispro. CMAJ. 1998;159(11):1353–5. No original data . [PMC free article: PMC1229846] [PubMed: 9861200]
58.
Mikhail N. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to Poulsen et al. Diabetes Care. 2004;27(7):1846–7. author reply 1847–8. No original data . [PubMed: 15220287]
59.
Mohn A, Marcovecchio M, Chiarelli F. et al. Insulin analogues [5] (multiple letters) New Engl J Med. 2005;352(17):1822–1824. No original data . [PubMed: 15858198]
60.
Moisey RS, Jenkins R, Nagi D. The use of basal insulin (NPH) compared with pre-mixed biphasic insulin in patients with type 2 diabetes mellitus. A single centre experience. Pract Diabetes Int. 2007;24(4):212–216. Exclude other reason .
61.
Nathan JP, Rosenberg JM. How are insulin glargine and insulin aspart different from the “older” insulins? Drug Topics. 2000;144(22):41. No original data .
62.
Nauck M A, Trautman M, Brodows R et al. Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267. Diabetologia 2007;50(7):1563–4. No original data . [PubMed: 17384924]
63.
Ning G, Xiang K, Gao Y. et al. Comparison of post-prandial blood glucose excursions between insulin lispro 75/25 and human insulin 70/30 in Chinese patients with type 1 or type 2 diabetes. International Journal of Medicine. 2005;9(2):14–22. Did not compare a premixed insulin analogue to another antidiabetic agent .
64.
Oosthuizen H. Insulin therapy in type 2 diabetes mellitus. J Endocrinol Metab Diabetes S Afr. 2003;8(3):72–78. No original data .
65.
Panczel P, Hosszufalusi N, Horvath MM. et al. Advantage of insulin lispro in suspected insulin allergy. Allergy. 2000;55(4):409–10. Exclude other reason . [PubMed: 10782533]
66.
Peragallo-Dittko V. Insulin therapy for type 2 diabetes. Diabetes Self-Management. 2003;20(5):17. No original data . [PubMed: 14679948]
67.
Plog T. Insulin analogs plus oral antidiabetic drug therapy for older patients with type 2 diabetes. Long-Term Care Interface 2007; 7. No original data .
68.
Renner R, Vocke K, Hepp KD. Blood Glucose Profiles in Type I and Type II Diabetic Patients under Different Insulin Mixtures of BHI-Regular and BHI-NPH. Munchener Medizinische Wochenschrift. 1983;125(Suppl 1):57–62. Non-English article . [PubMed: 6408436]
69.
Reviriego J, Herz M, Roach P. the Humalog® Mix25 Spanish Study Group. Improved glycaemic control without increased risk of hypoglycaemia with a 25% insulin/lispro 75% NPL mixture twice daily compared with NPH twice daily in patients with type 2 diabetes. J Appl Ther Res. 2004;4(4):3–9. Exclude other reason .
70.
Roach P, Strack T, Arora V. et al. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract. 2001;55(3):177–82. Did not evaluate a premixed insulin analogue . [PubMed: 11351771]
71.
Robertson D. Achieving fasting and postprandial blood glucose control in type 2 diabetes. Br J Hosp Med (Lond) 2006;67(10):518–22. No original data . [PubMed: 17069120]
72.
Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27(10):2495–7. Exclude other reason . [PubMed: 15451924]
73.
Schmoelzer I, de Campo A, Pressl H. et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2005;113(3):176–81. Does not apply to a key question . [PubMed: 15789278]
74.
Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes. 2006;114(1):41–2. No original data . [PubMed: 16450317]
75.
Shichiri M, Kishikawa H, Ohkubo Y. et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–9. Did not evaluate a premixed insulin analogue . [PubMed: 10860187]
76.
Sridhar GR. Two regimens of twice-daily premix insulin analogue: an observational study. Diabetes Res Clin Pract. 2006;71(1):105–7. Did not compare a premixed insulin analogue to another antidiabetic agent . [PubMed: 16171886]
77.
Swenson K, Brackenridge B. Lispro for type 2? Diabetes Forecast. 2000;53(7):81–83. No original data.
78.
Swenson K, Brackenridge B. Lispro insulin for improved glucose control in obese patient with type 2 diabetes. Diabetes Spectrum. 1998;11(1):13–15. No original data .
79.
Thaware P, Howe J, Lawrence IG. et al. Use of the rapid acting insulin analogue lispro and its protamine retarded from (Humalog Mix 25) in a clinical setting. Pract Diabetes Int. 2004;21(9):329–333. Did not compare a premixed insulin analogue to another antidiabetic agent .
80.
Valentine WJ, Palmer AJ, Lammert M. et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin. 2005;21(12):2063–71. No original data . [PubMed: 16368057]
81.
Walczak IM. Lantus reduces blood glucose levels, less hypoglycemia in treatment of type 2 diabetes. Diabetes Technol Ther. 2002;4(5):735–6. No original data . [PubMed: 12458566]
82.
Warren ML, Conway MJ, Klaff LJ. et al. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract. 2004;66(1):23–9. Did not compare a premixed insulin analogue to another antidiabetic agent . [PubMed: 15364158]
83.
White JR. Insulin glargine clinical trials. Clin Ther. 2004;26(7):1179–81. discussion 1182–3. No original data . [PubMed: 15336483]
84.
Yamada S, Watanabe M, Funae O. et al. Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. Intern Med. 2007;46(23):1893–7. Did not evaluate a premixed insulin analogue . [PubMed: 18057760]
85.
Yasuda H, Nagata M, Moriyama H. et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care. 2001;24(11):2008–9. Did not evaluate a premixed insulin analogue . [PubMed: 11679481]
86.
Zinman B. The pharmacokinetics of insulin analogues and pumps. Pract Diabetes Int. 2001;18(5 SUPPL):S3–S4. No original data .
Cover of Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes
Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet].
Comparative Effectiveness Reviews, No. 14.
Qayyum R, Wilson LM, Bolen S, et al.

Download

AHRQ (US Agency for Healthcare Research and Quality)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...